The StradomerTM Platform
GL-2045 is Gliknik's lead recombinant stradomerTM for autoimmune diseases. It has demonstrated potent efficacy in numerous animal models and is in IND-enabling manufacturing. StradomersTM are recombinant compounds designed to improve on pooled human intravenous immunoglobulin in a wide range of diseases including Myasthenia gravis and other neurological autoimmune disorders. They will also compete with antibody therapies used in immune disorders such as rheumatoid arthritis.